CAMBRIDGE, Mass., July 07, 2025 - Generation Bio Co. (Nasdaq: GBIO), a biotechnology company focused on T cell-driven autoimmune diseases, announced the granting of equity awards to a new employee under its 2025 Inducement Stock Incentive Plan. This grant, issued on July 1, 2025, includes non-statutory stock options to purchase 128,600 shares of the company's common stock at an exercise price of $0.32 per share, matching the closing price on the grant date. The stock options have a 10-year term, with a vesting schedule of 25% on the first anniversary of the employee's start date, and 6.25% vesting quarterly thereafter, contingent on continued employment with the company. The inducement grant adheres to the award agreements and the 2025 Inducement Stock Incentive Plan terms.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。